Intrapleural paclitaxel injection for ovarian and uterine cancer patients with malignant pleural effusions.

Intrapleural paclitaxel injection for ovarian and uterine cancer patients with malignant pleural effusions. - Intrapleural paclitaxel injection for malignant pleural effusions.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016527

Enrollment

Registered

2015-02-20

Start date

2015-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory and recurrent Ovarian cancer and Endometrial cancer with pleural effusion

Interventions

Intrapleural injection of paclitaxel

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Age 20 and over 2. Patients with a ECOG Performance Status, (P.S.) of 0, 1, or 2 3. Patients must have normal bone marrow, cardiac, hepatic, hematologic, and renal function. Must be obtained with 7 days prior to registration. Granulocytes >= 1500/mm3 Platelets >= 100,000/mm3 Hemoglobin >= 9.0g/dL Bilirubin <= 1.5mg/dL Creatinine <= 1.2 mg/dL 4. Patients must have signed an approved informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with active infection. 2. Patients with severe congestive heart failure, poorly controlled diabetes, poorly controlled hypertension, active bleeding etc.

Design outcomes

Primary

Measure	Time frame
The difference of mean drainage volume of pleural effusion between pre- and post-treatment	—

Countries

Japan

Contacts

Public ContactHidemichi Watari

Hokkaido University Hospital Department of Obstetrics and Gynecology

watarih@med.hokudai.ac.jp011-706-5941

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026